Maggie Aulsebrook completed her PhD studies at Monash University in 2017 with a thesis focused on the development of luminescent lanthanide chemosensors for the detection of biologically relevant species. Following this, she took up a position as a postdoctoral research fellow at Chimie ParisTech in the development of a library of compounds for the advancement of zirconium-89-based radiotracers for applications in PET. Maggie then joined ANSTO as a research radiochemist where she was involved in the development of the next generation of nuclear medicines for the diagnosis and therapy of human diseases. While at ANSTO her research spanned the development of novel radiopharmaceuticals for application in pre-clinical and clinical studies and in commercial production. To interface more closely with the clinic, Maggie moved to UCSF and focused on the development and clinical translation of GMP-grade research radiopharmaceuticals for first-in-human and investigational studies. Maggie has returned to Monash University and is leading the Radiochemistry Platform at Monash Biomedical Imaging (MBI). Maggie specialises in the development and clinical translation of radiopharmaceuticals. Throughout her career, she has led the development of a number of investigational radiopharmaceuticals for first-in-human application and provides expertise in the lifecycle of radiopharmaceuticals for clinical application.
NIF is hiring: As the Scientific Project Manager, you will be instrumental in driving the successful delivery of key initiatives within the National Imaging Facility.
10 September 2024
The groundbreaking Australian Mild Traumatic Brain Injury (AUS-mTBI) study will see thousands of volunteers from across the country who have had a recent concussion have the option to opt-in to repo
01 August 2024
16 March 2024
The Commonwealth Government Department of Education has today announced National Imaging Facility (NIF) will receive $28m under the National Collaborative Research Infrastructure Strategy (NCRIS), to
19 October 2023